BRIEF published on 11/24/2025 at 07:04, 9 months 17 days ago Medartis nomme un nouveau directeur financier Résultats Financiers Directeur Financier Medartis Transition Du Leadership Peter Hackel
BRIEF published on 11/24/2025 at 06:35, 9 months 17 days ago Victoria McLean Joins Julius Baer as Chief Compliance Officer Wealth Management Executive Board Julius Baer Compliance Officer Victoria McLean
BRIEF published on 11/24/2025 at 06:35, 9 months 17 days ago Victoria McLean rejoint Julius Baer en tant que responsable de la conformité Conseil D'administration Julius Baer Responsable De La Conformité Gestion De Patrimoine Victoria McLean
BRIEF published on 11/24/2025 at 06:35, 9 months 17 days ago Formycon Partners with NTC for Biosimilar Commercialization in Italy Formycon AG Ophthalmology Biosimilar Partnerships Italy Pharmaceutical Market FYB203/Baiama®
BRIEF published on 11/24/2025 at 06:35, 9 months 17 days ago Formycon s'associe à NTC pour la commercialisation de biosimilaires en Italie Formycon AG Ophtalmologie FYB203/Baiama® Partenariats En Matière De Biosimilaires Marché Pharmaceutique Italien
BRIEF published on 11/24/2025 at 06:34, 9 months 17 days ago Rieter Announces New Group Structure Innovation Market Position Group Structure Rieter AG Organizational Change
BRIEF published on 11/24/2025 at 06:34, 9 months 17 days ago Rieter annonce une nouvelle structure de groupe Innovation Position Sur Le Marché Changement Organisationnel Rieter AG Structure Du Groupe
BRIEF published on 11/23/2025 at 23:51, 9 months 17 days ago Hans-Joachim Watzke Steps Down as Managing Director of Borussia Dortmund Executive Board Borussia Dortmund Management Changes Hans-Joachim Watzke BVB E.V.
BRIEF published on 11/23/2025 at 23:51, 9 months 17 days ago Hans-Joachim Watzke quitte son poste de directeur général du Borussia Dortmund. Conseil D'administration Borussia Dortmund Changements De Direction Hans-Joachim Watzke BVB EV
BRIEF published on 11/23/2025 at 16:52, 9 months 18 days ago Bayer's Asundexian Achieves Key Endpoints in OCEANIC-STROKE Study Bayer Phase III Study Asundexian Stroke Prevention FXIa Inhibitor
Published on 09/11/2026 at 17:00, 3 hours 44 minutes ago Critical Elements Selected for Canada Investment Summit Prospectus, Showcasing Project to Leading Global Investors
Published on 09/11/2026 at 17:00, 3 hours 44 minutes ago Critical Elements sélectionné pour inclusion dans le prospectus du sommet Canadien de l'investissement, mettant le projet en valeur auprès d'investisseurs mondiaux de premier plan
Published on 09/11/2026 at 15:25, 5 hours 19 minutes ago Revolve Signs Agreement to Acquire 9.6 MW Operating Wind Project in the US and Secures Project-Level Debt Financing with EDC and Vancity
Published on 09/11/2026 at 15:00, 5 hours 44 minutes ago Regentis Biomaterials Reports First Half 2026 Financial Results and Provides Corporate Update
Published on 09/11/2026 at 14:30, 6 hours 14 minutes ago AIAI Holdings Enters into Extended Lock-up Agreements to Protect Long-Term Stockholder Value
Published on 09/11/2026 at 19:44, 1 hour ago DocMorris announces final conversion price and issue size of its New Convertible Bonds due 2031
Published on 09/11/2026 at 18:15, 2 hours 29 minutes ago CGTN: How BRICS creates new opportunities for Global South development
Published on 09/11/2026 at 18:00, 2 hours 44 minutes ago ROCTOOL: INFORMATION MENSUELLE RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET ACTIONS COMPOSANT LE CAPITAL SOCIAL
Published on 09/11/2026 at 07:00, 13 hours 44 minutes ago Transparantiekennisgeving van Baltisse Groep
Published on 09/11/2026 at 07:00, 13 hours 44 minutes ago Transparency notification by Baltisse Group
Published on 09/11/2026 at 07:00, 13 hours 44 minutes ago BIOPHYTIS ANNOUNCES COMPLETION OF €5.3 MILLION CAPITAL INCREASE TO FUND ITS PHASE 2 TRIAL IN OBESITY
Published on 09/11/2026 at 07:00, 13 hours 44 minutes ago BIOPHYTIS ANNONCE LA RÉALISATION D’UNE AUGMENTATION DE CAPITAL DE 5,3 MILLIONS D’EUROS DESTINÉE À FINANCER SON ESSAI DE PHASE 2 DANS L’OBÉSITÉ
